Rizatriptan

Rizatriptan acts as a selective 5HT1-receptor agonist. Its mechanism of action in migraine is believed to involve selective binding to 5HT1B/1D receptors, leading to cranial vasoconstriction and inhibition of pro-inflammatory neuropeptide release, thereby alleviating migraine symptoms.

Adult

BY MOUTH: 10 mg, dose to be taken as soon as possible after onset, followed by 10 mg after 2 hours if required (only if migraine recurs, patient not responding to initial dose should not take second dose for same attack).

Renal adjustment

Use with caution in renal impairment

Hepatic adjustment

Use with caution in hepatic impairment

Geriatric

Not licensed for use in elderly.

Max dose

20 mg per day

• Coronary vasospasm
• Ischaemic heart disease
• Peripheral vascular disease
• Previous cerebrovascular accident
• Previous myocardial infarction
• Previous transient ischaemic attack
• Prinzmetal’s angina
• Severe hypertension
• Uncontrolled hypertension
• Ischemic heart disease
• Coronary artery vasospasm
• Exposure to MAO inhibitor within preceding 2 weeks
• Within 24 hours of another triptan
• Within 24 hours of an ergot derivative
• Within 24 hours of SSRIs
• Within 24 hours of SNRIs